immunotherapy

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Greenwich LifeSciences expands FLAMINGO-01 trial with City of Hope, growing sites to 190-200. Preliminary data shows 70-80% recurrence reduction in breast cancer immunotherapy study.

AIM ImmunoTech ($AIMT) surged 73.66% after securing Japanese patent approval for Ampligen cancer therapy through 2039, strengthening its immuno-oncology portfolio.

$GLSI's GLSI-100 immunotherapy demonstrates 70-80% recurrence reduction in Phase III trial data accepted for AACR presentation.

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.

$SCNI warned by Nasdaq for trading below $1.00 for 30 consecutive days. Company has 180 days to restore compliance or face delisting.

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.

Junshi Biosciences wins NMPA approval for JS001sc, first domestic subcutaneous anti-PD-1 drug across 12 indications, delivering clinical parity with IV formulation.

Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.

Immunocore Holdings announced presentations at five major investor conferences in March 2026, showcasing its commercial-stage biotech platform and pipeline to institutional investors.

Greenwich LifeSciences boosts FLAMINGO-01 screening by 33% to 800 patients yearly, with non-HLA-A*02 arm fully enrolled and showing 80% recurrence reduction.

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.